Aligos Therapeutics
ALGS
52 hedge funds and large institutions have $612M invested in Aligos Therapeutics in 2021 Q1 according to their latest regulatory filings, with 9 funds opening new positions, 19 increasing their positions, 9 reducing their positions, and 8 closing their positions.
111% more repeat investments, than reductions
Existing positions increased: 19 | Existing positions reduced: 9
13% more first-time investments, than exits
New positions opened: 9 | Existing positions closed: 8
2% more funds holding
Funds holding: 51 → 52 (+1)
0% more funds holding in top 10
Funds holding in top 10: 3 → 3 (0)
0.03% less ownership
Funds ownership: 2.86% → 2.83% (-0.03%)
18% less capital invested
Capital invested by funds: $749M → $612M (-$137M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Janus Henderson Group
London,
United Kingdom
|
+$8.95M |
| 2 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
+$2.22M |
| 3 |
Wellington Management Group
Boston,
Massachusetts
|
+$1.91M |
| 4 |
Goldman Sachs
New York
|
+$1.11M |
| 5 |
Millennium Management
New York
|
+$867K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
DM
Deerfield Management
New York
|
-$16.6M |
| 2 |
LGM
Logos Global Management
San Francisco,
California
|
-$3.46M |
| 3 |
SFM
Sphera Funds Management
Tel Aviv,
Israel
|
-$2.05M |
| 4 |
AllianceBernstein
Nashville,
Tennessee
|
-$1.38M |
| 5 |
SSA
Schonfeld Strategic Advisors
New York
|
-$821K |
ALGS Hedge Fund Activity: Q1 2021 in Review
52 of the 5,695 institutional investors tracked by Wall St. Rank reported a position in Aligos Therapeutics (ALGS) for Q1 2021, worth a combined $612M — down 18% from $749M a quarter earlier.
Buyers outnumbered sellers: 9 funds opened new ALGS positions and 8 closed out — a net gain of 1 holder — while 19 added to existing stakes and 9 trimmed.
The largest buyer was Janus Henderson Group, adding an estimated $8.95M. The largest seller was Deerfield Management, exiting entirely with an estimated $16.6M sold.
- 52 institutional investors held Aligos Therapeutics (ALGS) as of Q1 2021, up from 51 in Q4 2020.
- Funds reported $612M of Aligos Therapeutics stock for Q1 2021, down 18% quarter-over-quarter.
- 9 funds opened new Aligos Therapeutics positions in Q1 2021 and 8 closed out, a net change of +1 holder.
- The largest Aligos Therapeutics buyer in Q1 2021 was Janus Henderson Group, an estimated $8.95M added.
- The largest Aligos Therapeutics seller in Q1 2021 was Deerfield Management, an estimated $16.6M sold.
Based on aggregated 13F filings for Q1 2021.